Indivior has failed in its bid to prevent a lawsuit claiming that it illegally blocked competition to opioid addiction drug Suboxone from coming to court in the US.
Shares in UK drugmaker Indivior have gone into freefall after it was charged by the US Department of Justice for fraudulently marketing its opioid addiction treatment.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh